Abstract

Purpose: We aim to systematically review and analyze the available literature on "exceptional responders" in oncology. We hypothesize that survival or patients with an exceptional response may be predicted based on clinical factors. Materials and Methods: A PICOS/PRISMA/MOOSE selection protocol was used to find studies that reported oncology patients with an exceptional response. A total of 333 initial articles were screened, and 76 articles were included, accounting for 85 patients. The primary outcome was survival after exceptional response therapy (ERT). The secondary outcome was survival since diagnosis. Univariate and multivariate analyses were conducted for both outcomes with 17 covariates. Results: The median age was 52 years (interquartile range, 35-66 y), 51.8% were male individuals, 18 (21.2%) had lung cancer, and 1 patient (1%) met all National Cancer Institute criteria for exceptional response. The most common treatment resulting in exceptional response was a form of chemotherapy (49.2%) followed by targeted therapy (26.8%) and radiation therapy (7.7%). The median time from diagnosis to initiation of ERT was 7.92 months (interquartile range, 0-24.72 mo). On multivariate analysis of survival after initiation of ERT, there were no predictors of exceptional response. On multivariate analysis of survival since diagnosis, predictors of prolonged survival included time between diagnosis and ERT initiation (hazard ratio, 0.52; 95% confidence interval, 0.32-0.87; P=0.0124) and single prior surgery versus none (0.08; 95% confidence interval, 0.01-0.98; P=0.04853). Conclusions: There were no clinically apparent patient or treatment factors that predicted favorable survival following ERT; instead, reporting of exceptional response appears to be biased.

Original languageEnglish (US)
Pages (from-to)624-635
Number of pages12
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume42
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Meta-Analysis
Survival
Multivariate Analysis
Therapeutics
Confidence Intervals
National Cancer Institute (U.S.)
Lung Neoplasms
Radiotherapy
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{3f6601e3b0694455b3bd2288412ed043,
title = "Exceptional responders in oncology: A systematic review and meta-analysis of patient level data",
abstract = "Purpose: We aim to systematically review and analyze the available literature on {"}exceptional responders{"} in oncology. We hypothesize that survival or patients with an exceptional response may be predicted based on clinical factors. Materials and Methods: A PICOS/PRISMA/MOOSE selection protocol was used to find studies that reported oncology patients with an exceptional response. A total of 333 initial articles were screened, and 76 articles were included, accounting for 85 patients. The primary outcome was survival after exceptional response therapy (ERT). The secondary outcome was survival since diagnosis. Univariate and multivariate analyses were conducted for both outcomes with 17 covariates. Results: The median age was 52 years (interquartile range, 35-66 y), 51.8{\%} were male individuals, 18 (21.2{\%}) had lung cancer, and 1 patient (1{\%}) met all National Cancer Institute criteria for exceptional response. The most common treatment resulting in exceptional response was a form of chemotherapy (49.2{\%}) followed by targeted therapy (26.8{\%}) and radiation therapy (7.7{\%}). The median time from diagnosis to initiation of ERT was 7.92 months (interquartile range, 0-24.72 mo). On multivariate analysis of survival after initiation of ERT, there were no predictors of exceptional response. On multivariate analysis of survival since diagnosis, predictors of prolonged survival included time between diagnosis and ERT initiation (hazard ratio, 0.52; 95{\%} confidence interval, 0.32-0.87; P=0.0124) and single prior surgery versus none (0.08; 95{\%} confidence interval, 0.01-0.98; P=0.04853). Conclusions: There were no clinically apparent patient or treatment factors that predicted favorable survival following ERT; instead, reporting of exceptional response appears to be biased.",
author = "Mackenzie Cummings and Lehrer, {Eric J.} and Joseph Drabick and Gusani, {Niraj J.} and Trifiletti, {Daniel M.} and Nicholas Zaorsky",
year = "2019",
month = "8",
day = "1",
doi = "10.1097/COC.0000000000000572",
language = "English (US)",
volume = "42",
pages = "624--635",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

Exceptional responders in oncology : A systematic review and meta-analysis of patient level data. / Cummings, Mackenzie; Lehrer, Eric J.; Drabick, Joseph; Gusani, Niraj J.; Trifiletti, Daniel M.; Zaorsky, Nicholas.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 42, No. 8, 01.08.2019, p. 624-635.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Exceptional responders in oncology

T2 - A systematic review and meta-analysis of patient level data

AU - Cummings, Mackenzie

AU - Lehrer, Eric J.

AU - Drabick, Joseph

AU - Gusani, Niraj J.

AU - Trifiletti, Daniel M.

AU - Zaorsky, Nicholas

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Purpose: We aim to systematically review and analyze the available literature on "exceptional responders" in oncology. We hypothesize that survival or patients with an exceptional response may be predicted based on clinical factors. Materials and Methods: A PICOS/PRISMA/MOOSE selection protocol was used to find studies that reported oncology patients with an exceptional response. A total of 333 initial articles were screened, and 76 articles were included, accounting for 85 patients. The primary outcome was survival after exceptional response therapy (ERT). The secondary outcome was survival since diagnosis. Univariate and multivariate analyses were conducted for both outcomes with 17 covariates. Results: The median age was 52 years (interquartile range, 35-66 y), 51.8% were male individuals, 18 (21.2%) had lung cancer, and 1 patient (1%) met all National Cancer Institute criteria for exceptional response. The most common treatment resulting in exceptional response was a form of chemotherapy (49.2%) followed by targeted therapy (26.8%) and radiation therapy (7.7%). The median time from diagnosis to initiation of ERT was 7.92 months (interquartile range, 0-24.72 mo). On multivariate analysis of survival after initiation of ERT, there were no predictors of exceptional response. On multivariate analysis of survival since diagnosis, predictors of prolonged survival included time between diagnosis and ERT initiation (hazard ratio, 0.52; 95% confidence interval, 0.32-0.87; P=0.0124) and single prior surgery versus none (0.08; 95% confidence interval, 0.01-0.98; P=0.04853). Conclusions: There were no clinically apparent patient or treatment factors that predicted favorable survival following ERT; instead, reporting of exceptional response appears to be biased.

AB - Purpose: We aim to systematically review and analyze the available literature on "exceptional responders" in oncology. We hypothesize that survival or patients with an exceptional response may be predicted based on clinical factors. Materials and Methods: A PICOS/PRISMA/MOOSE selection protocol was used to find studies that reported oncology patients with an exceptional response. A total of 333 initial articles were screened, and 76 articles were included, accounting for 85 patients. The primary outcome was survival after exceptional response therapy (ERT). The secondary outcome was survival since diagnosis. Univariate and multivariate analyses were conducted for both outcomes with 17 covariates. Results: The median age was 52 years (interquartile range, 35-66 y), 51.8% were male individuals, 18 (21.2%) had lung cancer, and 1 patient (1%) met all National Cancer Institute criteria for exceptional response. The most common treatment resulting in exceptional response was a form of chemotherapy (49.2%) followed by targeted therapy (26.8%) and radiation therapy (7.7%). The median time from diagnosis to initiation of ERT was 7.92 months (interquartile range, 0-24.72 mo). On multivariate analysis of survival after initiation of ERT, there were no predictors of exceptional response. On multivariate analysis of survival since diagnosis, predictors of prolonged survival included time between diagnosis and ERT initiation (hazard ratio, 0.52; 95% confidence interval, 0.32-0.87; P=0.0124) and single prior surgery versus none (0.08; 95% confidence interval, 0.01-0.98; P=0.04853). Conclusions: There were no clinically apparent patient or treatment factors that predicted favorable survival following ERT; instead, reporting of exceptional response appears to be biased.

UR - http://www.scopus.com/inward/record.url?scp=85070451072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070451072&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000572

DO - 10.1097/COC.0000000000000572

M3 - Review article

C2 - 31313679

AN - SCOPUS:85070451072

VL - 42

SP - 624

EP - 635

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 8

ER -